MAP2K7 and ovarian cancer: MEK inhibitors have also been investigated in combination with inhibitors that increase the expression of BH3 pro-apoptosis proteins and inhibit anti-apoptosis proteins (Bcl-2, Bcl-xL) resulting in a greater reduction in proliferation and survival in ovarian cancer cell lines [39].